The place of tumor necrosis factor alpha inhibitors in the treatment of rheumatoid arthritis patients: tactics in different variants of the disease
As the period of use of genetically engineered biologic drugs (GEBD) in clinical practice is growing, clinicians are faced with new questions: how to switch from one GEBD to another in case of primary or secondary inefficacy, intolerance to previous GEBD therapy; what should be done after low diseas...
Main Author: | N. V. Chichasova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2015-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/180 |
Similar Items
-
Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01) -
The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01) -
Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01) -
Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01) -
A CURRENT VIEW ON THE PROBLEM OF RAPIDLY PROGRESSIVE RHEUMATOID ARTHRITIS
by: Dmitry Evgenyevich Karateyev
Published: (2010-06-01)